– USA, WA – Anavasi Diagnostics, an NIH/RADx medical technology company focused on the development of novel molecular diagnostic testing, recently today announced the election of Dr. Bryan Crane (PhD), Arthur Kirsch, and David Vied to its Board as outside Directors.
“We are thankful to have these three talented individuals join the board. They all bring valuable personal perspectives and professional experience to the Board that will greatly contribute to the growth of Anavasi as we complete our clinical trials, broaden our product development and portfolio, and work towards commercialization,” said CEO, Nelson Patterson.
Mr. Crane, Mr. Kirsch, and Mr. Vied join a seasoned executive team of the Board of Directors, led by the President and CEO, Nelson Patterson.
About Dr. Bryan Crane
Dr. Bryan Crane is currently VP, Head of System Design at Illumina (NSDQ: ILMN), a global leader in the field of instrumentation for genomic analysis. Dr. Crane has served in R&D at Illumina for 15 years and has been deeply involved in the innovation and productization of several generations of market-leading instrumentation and consumable platforms. Dr. Crane is responsible for the collaborative optimization of product architecture, prioritizing R&D investment, evolving the development process, and maintaining partnerships with worldwide suppliers. He is also responsible for growing and developing a large engineering team, instilling Illumina’s innovative, fast-moving R&D culture.
About Arthur Kirsch
Arthur Kirsch is currently a director of Liquidia Corp. (Nasdaq: LQDA) a biopharmaceutical company focused on the development and commercialization of products for pulmonary hypertension. He has served on several public company boards, typically as an audit committee member. Arthur had a 40+ year career (Drexel Burnham, Vector Securities, GCA Global) in investment banking working with a variety of companies, from start-ups to large public entities. He specialized in healthcare, advising companies on everything from capital raising to strategic transactions.
About David Vied
David L. Vied is the Global Sector Leader for the Medical Devices practice for Korn Ferry. He additionally serves as a director of Cyanotech Corporation (Nasdaq: CYAN), a developer and marketer of microalgae-based nutritional supplements. For over 25 years, David has advised medical device clients on talent management and talent assessment issues, addressing such topics as CEO succession, innovation and transformation acceleration, and executive development. He has conducted search assignments in areas that range from medical affairs, research and development, and regulatory compliance to CEO and board roles. His clients run the gamut of the industry, from pre-revenue start-ups to established and dominant multi-billion-dollar market cap environments.
About Anavasi Diagnostics
Anavasi Diagnostics is a rapidly growing medical technology company focused on developing novel molecular diagnostic testing using a proprietary reverse transcriptase methodology (patent-pending). As a spin-out of the University of Washington, Anavasi’s technology platform was designed by renowned researchers in UW’s bioengineering department. The Company’s quest to successfully commercialize this technology is led by top medical device and clinical diagnostics executives, manufacturing experts, and a former Microsoft software veteran. The team’s combined experience has been responsible for introducing more than forty medical/diagnostic products and hundreds of peer-reviewed research publications.
To date, Anavasi has completed a $6.0 million Seed Round (convertible note), a $2.6 million Founder’s Round, and is currently raising funds in a previously announced $20M Series A round. In November 2021, the company was awarded $14.9 million from the National Institutes of Health Rapid Acceleration of Diagnostics initiative to accelerate the launch and broad market availability of the AscencioDx molecular diagnostic platform for the detection of RNA indicative of the SARS-CoV-2 / COVID-19 virus.
For more information: https://www.anavasidx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
